[1] Djuikwo-Teukeng FF, Kouam Simo A, Allienne JF, et al. Population genetic structure of Schistosoma bovis in Cameroon. Parasite, 2019, 12(1): 56-57.
[2] 龚怡, 付倩, 张蓓. 多层螺旋CT检查肝脏体积对乙型肝炎肝硬化患者肝脏受损程度的量化诊断价值分析. 实用肝脏病杂志, 2018, 21(6): 895-898.
[3] El-Khadragy MF, Al-Olayan EM, Elmallah MIY, et al. Probiotics and yogurt modulate oxidative stress and fibrosis in livers of Schistosoma mansoni-infected mice. Comp Altern Med, 2019, 19(1): 3-4.
[4] Ma Z, Liu X, Dong H, et al. Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice. Parasite, 2018, 117(9): 2831-2839.
[5] 胡海东, 张见增. 216例肝硬化门静脉高压症患者CT血管成像门静脉侧支血管表现研究. 实用肝脏病杂志, 2016, 19(1): 73-76.
[6] Guan Bing, Li Xiao-Hong, Wang Liang,et al. Gastric fundus splenosis with hemangioma masquerading as a gastrointestinal stromal tumor in a patient with schistosomiasis and cirrhosis who underwent splenectomy: A case report and literature review. Medicine,2018, 97(27): 121-125.
[7] Koslowski N, Sombetzki M, Loebermann M, et al. Single-sex infection with female schistosoma mansoni cercariae mitigates hepatic fibrosis after secondary infection. Plo Negl Trop Dis, 2017 , 11(5): 555-556.
[8] Zheng L, Hu Y, Wang Y, et al. Recruitment of neutrophils mediated by Vγ2 γδ T cells deteriorates liver fibrosis induced by Schistosoma Japonicum infection in C57BL/6 mice. Infection, 2017, 85(8): 1020-1016.
[9] Elhenawy AA, Ashour RH, Nabih N, et al. Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis. Parasitol Int, 2017, 66(5): 545-554.
[10] Wang Q, Chou X, Guan F, et al. Enhanced wnt signalling in hepatocytes is associated with Schistosoma Japonicum infection and contributes to liver fibrosis. Sci Rep, 2017, 7(1): 230-231.
[11] Cascales-Campos PA, Romero PR, Schneider MA, et al. Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant? Eur J Radiol, 2017, 91(3): 155-159.
[12] Yun EY, Kim TH, Lee SS, et al. A Case of composite hepatocellular carcinoma and neuroendocrine carcinoma in a patient with liver cirrhosis caused by chronic hepatitis B. Kor J Gastro, 2016, 68(2): 109-113.
[13] Mu K, Zhang J, Gu Y, et al. Cord-derived mesenchymal stem cells therapy for liver cirrhosis in children with refractory Henoch-Schonlein purpura: A case report. Medicine, 2018, 97(47): 13287-13288.
[14] Agraz-Cibrián JM, Delgado-Rizo V, Segura-Ortega JE, et al. Impaired neutrophil extracellular traps and inflammatory responses in the peritoneal fluid of patients with liver cirrhosis. Scand J Imm, 2018, 88(5): 12714-12715.
[15] Abd Alla MDA, El Awady MK, Dawood RM, et al. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. Arch Virol, 2018, 163(10): 2765-2774.
[16] Wen X, Yao M, Lu Y, et al. Integration of prealbumin into Child-Pugh classification improves prognosis predicting accuracy in HCC patients considering curative surgery. J Clin Transl, 2018, 6(4): 377-384.
[17] Garbuzenko DV, Arefyev NO, Kazachkov EL. Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. Wor J Gastroenterol, 2018, 24(33): 3738-3748.
[18] Di Pascoli M1, Sacerdoti D, Pontisso P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis. J Vasc Res, 2017, 54(2): 92-99.
[19] Talaki E, Schaffellner S, Kniepeiss D, et al. CT perfusion imaging of the liver and the spleen in patients with cirrhosis: Is there a correlation between perfusion and portal venous hypertension? Eur Radiol, 2017, 27(10): 4173-4180.
[20] Li JP, Feng GL, Li DQ, et al. Detection and differentiation of early hepatocellular carcinoma from cirrhosis using CT perfusion in a rat liver model. Hepatobiliary Pancreat Dis Int, 2016, 15(6): 612-618. |